Observational Metabolic Health Study

Exclusion Criteria

• •Do not have a personal smartphone, internet access, or unwilling to download Chloe.
• •Concomitant Therapies:
• •GLP-1 receptor agonists and related incretin mimetics, (e.g. semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), sitagliptin (Januvia, Janumet), saxagliptin (Onglyza, Komblglyze), alogliptin (Nesina, Kazano, Oseni), linagliptin (Tradjenta, Jentadueto) or tirzepatide (Mounjaro))
• •Hormone Replacement Therapy (especially fluctuating/ cycle mimicking dose) or Hormonal Contraceptives (oral or IUD)
• •Participants receiving any investigational therapies or treatments within 30 days prior to randomization.
• •Concurrent participation in any other investigational study during the study period.
• •Regular use of over-the-counter allergy or pain medications (including ibuprofen, acetaminophen, aspirin, naproxen, diphenhydramine, cetirizine, loratadine, fexofenadine ) (\>3-4 times/week).
• •Other Illnesses or Conditions: Participants who have the following comorbidities or conditions are excluded:
• •Currently or previously diagnosed with Obesity (BMI greater than 29.9)
• •Known diagnosis of Type 1 or Type 2 Diabetes Mellitus requiring medical intervention.
• •Known diagnosis of an eating disorder
• •Currently diagnosed with Alcohol Abuse and/or Substance Use Disorder
• •Women not yet in menopause (Have had a menstrual period within the last 12 months)
• •Currently diagnosed with Anemia
• •Significant cardiovascular disease or severe cardiac event, except hypertension.
• •Current or past diagnosis with cancer of any kind, except non-melanoma skin cancer
• •Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes.
• •Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
• •Have undergone a major change in diet or on a special diet (e.g. intermittent fasting, carnivore diet, keto diet, vegan/vegetarian, extending fasting etc.) 60 days prior to enrollment or who initiated such a change at any time during the study.
• •Recent weight fluctuations (greater than 10% in the last six months)
• •Smoker or use of tobacco or nicotine products.
• •Regular use of any cannabis, THC, or CBD containing products or unwillingness to cease use of such products 1 week prior to randomization and throughout the duration of the study period.
• •Alcohol use exceeding 14 units/week or unwillingness to change drinking habits to 14 or less units/week 1 week prior to randomization and throughout the duration of the study period
• •Known hypersensitivity or previous allergic reaction to nicotinamide, palmitoylethanolamide, oleoylethanolamide, spermidine
• •Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.